Merck 2010 Annual Report Download - page 79



The Process Solutions Business Unit supplies products used to manufacture biopharmaceutical
drugs. It accounts for about 40% of the division’s total revenues. The business unit enables
pharmaceutical and biotechnology companies to develop and manufacture clinical and com-
mercial drug materials safely and efficiently. By combining the resources of Millipore and
Merck, we can expand our portfolio of integrated bioprocessing technologies and offer an
attractive range of development and regulatory services to biopharmaceutical manufacturers.

Products offered by the Process Solutions Business Unit support clarification, purification, viral
clearance, sterile filtration, process monitoring and process development through scale-up to
full-scale production. The portfolio helps ensure biological safety, for example with products
for sterile and virus filtration as well as hardware and support for downstream processing.
With a comprehensive range of products and services for purification, e.g. ultrafiltration and
chromatography, Merck Millipore helps biopharmaceutical developers and manufacturers to
efficiently and effectively purify biologic drugs. Some of the products within this portfolio
include Pelicon ® for tangential flow filtration, Millistak ® Pod and Prostakfor clarification,
ChromaSorb, and ProSep ® chromatography media. The purification portfolio is complemented
by Fractogel ® and Eshmuno ® from the Merck chromatography business.

The Mobius ® single-use product line provides integrated solutions that bring together Merck
Millipore’s advanced separation technologies, differentiated single-use products, applications
expertise, and expert validation support. Mobius ® FlexReady Solutions are optimized, complete
single-use solutions that integrate process-ready hardware systems with Mobius ® Flexware
assemblies.
As it eliminates the time-consuming steps involved in cleaning, autoclaving and assembling,
the Mobius ® CellReady 3L single-use, stirred tank bioreactor considerably reduces the downtime
typical of glass bioreactors. This enables process development engineers to focus more on exper-
imentation and data analysis in order to obtain results faster.

Moreover, the business unit’s portfolio covers the entire pharmaceutical production value chain.
Apart from regulated starting materials and active pharmaceutical ingredients, our pharmaceutical
raw materials, for example from the Parteck ® range, are used as excipients for the production
of solid, semi-solid, and liquid formulations. Cell culture supplements complement the range of
products and services for upstream processing. Merck has combined its range of excipients and
active ingredients for pharmaceutical production processes under the Emprove ® brand.
Products and services support
developers and manufacturers of
biopharmaceuticals
The business unit’s portfolio
covers the entire pharmaceutical
production value chain
Company 75Management Report Corporate governance Consolidated Financial Statements More information
Merck Millipore